NEW YORK (GenomeWeb) – Health plan management firm MagnaCare has signed a deal to provide GenTox's pharmacogenomic testing services to members of its provider network, the companies announced today.

"This initiative promises to provide doctors with the valuable information they need to achieve more efficient dosing of critical medications and provides access to information for the most effective choices based upon each patient’s unique genetic makeup obtained through the testing," MagnaCare CEO Joseph Berardo said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.